SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aadi Bioscience, Inc. – ‘10-K’ for 12/31/23 – ‘ZIP’

On:  Wednesday, 3/13/24, at 4:19pm ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-10901   ·   File #:  1-38560

Previous ‘10-K’:  ‘10-K’ on 3/29/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   12 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/24  Aadi Bioscience, Inc.             10-K       12/31/23   81:12M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.35M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     41K 
 3: EX-21.1     Subsidiaries List                                   HTML     23K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML     23K 
 9: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     44K 
                Awarded Compensation                                             
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
15: R1          Cover Page                                          HTML     91K 
16: R2          Audit Information                                   HTML     28K 
17: R3          Consolidated Balance Sheets                         HTML    118K 
18: R4          Consolidated Balance Sheets (Parenthetical)         HTML     43K 
19: R5          Consolidated Statements of Operations and           HTML    105K 
                Comprehensive Loss                                               
20: R6          Consolidated Statements of Stockholders' Equity     HTML     81K 
21: R7          Consolidated Statements of Cash Flows               HTML    117K 
22: R8          Nature of Organization and Operations               HTML     32K 
23: R9          Summary of Significant Accounting Policies          HTML    105K 
24: R10         Fair Value Measurement                              HTML     60K 
25: R11         Short-Term Investments and Cash Equivalents         HTML     59K 
26: R12         Intangible Asset                                    HTML     32K 
27: R13         Accrued Liabilities                                 HTML     36K 
28: R14         Operating Leases                                    HTML     51K 
29: R15         License Agreements                                  HTML     32K 
30: R16         Stockholders' Equity                                HTML     36K 
31: R17         Share-Based Compensation                            HTML     76K 
32: R18         Employee Stock Purchase Plan                        HTML     34K 
33: R19         Income Taxes                                        HTML     66K 
34: R20         Commitments and Contingencies                       HTML     32K 
35: R21         Employee Retirement Plan                            HTML     29K 
36: R22         Summary of Significant Accounting Policies          HTML    123K 
                (Policies)                                                       
37: R23         Summary of Significant Accounting Policies          HTML     77K 
                (Tables)                                                         
38: R24         Fair Value Measurement (Tables)                     HTML     59K 
39: R25         Short-Term Investments and Cash Equivalents         HTML     62K 
                (Tables)                                                         
40: R26         Intangible Asset (Tables)                           HTML     29K 
41: R27         Accrued Liabilities (Tables)                        HTML     36K 
42: R28         Operating Leases (Tables)                           HTML     52K 
43: R29         Share-Based Compensation (Tables)                   HTML     66K 
44: R30         Employee Stock Purchase Plan (Tables)               HTML     31K 
45: R31         Income Taxes (Tables)                               HTML     60K 
46: R32         Nature of Organization and Operations (Detail)      HTML     56K 
47: R33         Summary of Significant Accounting Policies -        HTML     77K 
                Narrative (Detail)                                               
48: R34         Summary of Significant Accounting Policies -        HTML     32K 
                Schedule of Cash, Cash Equivalents and Restricted                
                Cash (Details)                                                   
49: R35         Summary of Significant Accounting Policies -        HTML     31K 
                Schedule of Inventory (Details)                                  
50: R36         Summary of Significant Accounting Policies -        HTML     45K 
                Property and Equipment (Details)                                 
51: R37         Summary of Significant Accounting Policies -        HTML     31K 
                Gross-to-Net Sales Adjustments (Details)                         
52: R38         Summary of Significant Accounting Policies -        HTML     33K 
                Schedule of Outstanding Potentially Dilutive                     
                Securities Excluded in Calculation of Diluted Net                
                Loss per Share (Detail)                                          
53: R39         Fair Value Measurement - Asset and Liabilities      HTML     76K 
                Measured on Recurring Basis (Details)                            
54: R40         Short-Term Investments and Cash Equivalents         HTML     52K 
                (Details)                                                        
55: R41         Intangible Asset - Narrative (Details)              HTML     34K 
56: R42         Intangible Asset - Schedule of Estimated            HTML     31K 
                Amortization Expense Related to Definite Lived                   
                Intangible Asset (Detail)                                        
57: R43         Accrued Liabilities - Schedule of Accrued           HTML     41K 
                Liabilities (Detail)                                             
58: R44         Operating Leases - Narrative (Detail)               HTML     37K 
59: R45         Operating Leases - Schedule of Information Related  HTML     33K 
                to Lease (Detail)                                                
60: R46         Operating Leases - Schedule of Rent Expense         HTML     27K 
                (Detail)                                                         
61: R47         Operating Leases - Schedule of Future Minimum       HTML     48K 
                Lease Payments Required under Operating Lease                    
                (Detail)                                                         
62: R48         License Agreements (Detail)                         HTML     63K 
63: R49         Stockholders' Equity (Detail)                       HTML     83K 
64: R50         Share-Based Compensation - Narrative (Detail)       HTML    103K 
65: R51         Share-Based Compensation - Schedule of Stock        HTML     71K 
                Option Activity (Detail)                                         
66: R52         Share-Based Compensation - Schedule of Recognized   HTML     58K 
                Compensation Cost Restricted Stock Units (Details)               
67: R53         Share-Based Compensation - Schedule of Recognized   HTML     30K 
                Compensation Cost Related to Employee and                        
                Non-employee Stock-Based Compensation Activity                   
                (Detail)                                                         
68: R54         Share-Based Compensation - Stock Options Valuation  HTML     48K 
                Assumptions (Detail)                                             
69: R55         Employee Stock Purchase Plan - Narrative (Details)  HTML     58K 
70: R56         Employee Stock Purchase Plan - Calculation          HTML     55K 
                Assumptions (Details)                                            
71: R57         Income Taxes - Narrative (Detail)                   HTML     46K 
72: R58         Income Taxes - Schedule of Reconciliation of        HTML     42K 
                Statutory Federal Income Tax (Detail)                            
73: R59         Income Taxes - Schedule of Significant Components   HTML     47K 
                of Deferred Tax Assets and Liabilities (Detail)                  
74: R60         Income Taxes - Schedule of Changes to Gross         HTML     30K 
                Unrecognized Tax Benefits (Detail)                               
75: R61         Commitments and Contingencies - Narrative (Detail)  HTML     35K 
76: R62         Employee Retirement Plan (Details)                  HTML     25K 
78: XML         IDEA XML File -- Filing Summary                      XML    140K 
81: XML         XBRL Instance -- aadi-20231231_htm                   XML   1.32M 
77: EXCEL       IDEA Workbook of Financial Report Info              XLSX    108K 
11: EX-101.CAL  XBRL Calculations -- aadi-20231231_cal               XML    178K 
12: EX-101.DEF  XBRL Definitions -- aadi-20231231_def                XML    524K 
13: EX-101.LAB  XBRL Labels -- aadi-20231231_lab                     XML   1.46M 
14: EX-101.PRE  XBRL Presentations -- aadi-20231231_pre              XML    934K 
10: EX-101.SCH  XBRL Schema -- aadi-20231231                         XSD    153K 
79: JSON        XBRL Instance as JSON Data -- MetaLinks              467±   658K 
80: ZIP         XBRL Zipped Folder -- 0001628280-24-010901-xbrl      Zip   1.88M 


‘ZIP’   —   XBRL Zipped Folder — 0001628280-24-010901-xbrl


This is an XBRL Zipped Folder.

        Download this zipped .zip folder
 
Files:aadi-20231231.htm
aadi-20231231.xsd
aadi-20231231_cal.xml
aadi-20231231_def.xml
aadi-20231231_g1.jpg
aadi-20231231_g2.jpg
aadi-20231231_g3.jpg
aadi-20231231_g4.jpg
aadi-20231231_g5.jpg
aadi-20231231_g6.jpg
aadi-20231231_g7.jpg
aadi-20231231_g8.jpg
aadi-20231231_g9.jpg
aadi-20231231_lab.xml
aadi-20231231_pre.xml
aadi-20231231xex211.htm
aadi-20231231xex231.htm
aadi-20231231xex311.htm
aadi-20231231xex312.htm
aadi-20231231xex321.htm
aadi-20231231xex322.htm
aadi-20231231xex41.htm
aadi-20231231xex971.htm


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/03/24  Aadi Bioscience, Inc.             424B5                  1:219K                                   Donnelley … Solutions/FA


11 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/02/23  Aadi Bioscience, Inc.             8-K:5,7,9   9/27/23   15:537K                                   Donnelley … Solutions/FA
 3/29/23  Aadi Bioscience, Inc.             10-K       12/31/22   92:31M                                    Workiva Inc Wde… FA01/FA
12/07/22  Aadi Bioscience, Inc.             8-K:5,9    12/06/22   11:355K                                   Donnelley … Solutions/FA
 9/22/22  Aadi Bioscience, Inc.             8-K:1,3,7,9 9/22/22   14:632K                                   Donnelley … Solutions/FA
 5/12/22  Aadi Bioscience, Inc.             10-Q        3/31/22   64:9.5M                                   ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             10-K       12/31/21   84:13M                                    ActiveDisclosure/FA
 3/17/22  Aadi Bioscience, Inc.             8-K:1,9     3/17/22   12:392K                                   Donnelley … Solutions/FA
11/10/21  Aadi Bioscience, Inc.             10-Q        9/30/21   76:12M                                    ActiveDisclosure/FA
 8/27/21  Aadi Bioscience, Inc.             8-K:1,2,3,5 8/26/21   26:11M                                    Donnelley … Solutions/FA
 5/17/21  Aadi Bioscience, Inc.             8-K:1,3,5,7 5/16/21    5:1.3M                                   Donnelley … Solutions/FA
 3/15/18  Aadi Bioscience, Inc.             10-K       12/31/17   74:8.6M                                   ActiveDisclosure/FA
Top
Filing Submission 0001628280-24-010901   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 6:51:59.1am ET